Evogene, which develops genetically enhanced seeds to elevate crop performance and productivity, filed on Monday with the SEC to raise up to $60 million in an initial public offering. The company's shares are currently traded on the Tel Aviv Stock Exchange under the ticker EVGN. The Rehovot, Israel-based company, which was founded in 2000 and booked $18 million in sales for the 12 months ended June 30, 2013, plans to list on the NYSE under the symbol EVGN. Evogene initially filed confidentially on April 26, 2013. Credit Suisse and Deutsche Bank are the joint bookrunners on the deal. No pricing terms were disclosed.
